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We have developed an in vitro system to study the 
interactions between biliary epithelium and lympho-
cytes using cultured human biliary epithelial cells. No 
class II antigens were detected by immunoperoxidase 
staining of the normal biliary epithelial cells, but 
alloactivated lymphocyte culture supernatants were 
able to induce class II expression. The activity of the 
supernatants was blocked with an anti-y-interferon 
monoclonal antibody. In addition, recombinant human 
y-interferon alone induced the expression of class II 
antigens and increased the intensity of class I staining 
of cultured biliary epithelial cells.· Biliary epithelial 
cell-induced proliferation of alloreactive T lympho-
cytes demonstrated that the major histocompatibility 
complex molecules carry functional lymphocyte-
activating determinants. The recognition of major 
histocompatibility complex determinants was con-
firmed by monoclonal antibody-blocking studies and 
by stimulation of an alloreactive T-cell clone. However, 
the biliary epithelial cells were much less potent 
stimulators than arterial endothelial cells tested in the 
same assay system. (HEPATOLOGY 1991;13:239-246.) 
The biliary epithelium is a major target oflymphocytic 
attack in human liver allograft rejection and in many 
immunologically mediated liver diseases such as PBC 
(1,2). The immune damage in these disorders is thought 
to be mediated primarily by T cells. Major histocompat-
ibility complex (MHC) antigens are likely the target of 
lymphocytic attack in rejection (3), and, although the 
target antigens in PBC have not yet been identified, the 
aberrant expression of class II antigens seen on the bile 
ducts in PBC livers has been hypothesized to playa role 
in the disease (4). 
The biliary epithelium in normal livers expresses class 
I but not class II human leukocyte antigens (HLA) (5-7). 
However, all three class II subregion products, namely 
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HLA-DR, HLA-DP and HLA-DQ, have been detected on 
bile ducts in transplanted livers during rejection and 
other complications (5, 8), in hepatic graft vs. host 
disease after bone marrow transplantation (9) and in 
PBC (4). It has been hypothesized that this expression is 
induced by soluble inflammatory mediators released 
from the invading mononuclear cells. Although the 
pathogenic role of this aberrant class II expression is 
unclear, we have previously shown that the increased 
destruction of bile duct epithelium during rejection is 
associated with HLA class II-specific lymphocytes in-
vading the allograft (10). 
We have established an in vitro model system to study 
the interactions between biliary epithelium and lympho-
cytes using cultured normal human biliary epithelial 
cells (BEC). The cultured BEC have been used to 
investigate the cytokines responsible for the up-
regulation of class II MHC antigens and whether these 
MHC molecules were functionally active (i.e., capable of 
stimulating T lymphocytes). The results obtained for 
BEC have been compared with arterial endothelial cells 
(AEC), which have already been shown to be potent 
allogeneic stimulators of lymphocyte proliferation. 
MATERIALS AND METHODS 
Isolation and Culture of BEe. BEC cultures were estab-
lished using a modification of a technique previously published 
for the isolation of intrahepatic BEC (11). The use of human 
tissues in these studies was approved by the internal review 
board. Because whole donor livers are rarely available for 
research purposes, an unused section of the common bile duct 
from donor livers was the source of cells in this study. Any 
excess connective tissue was removed, and the duct was opened 
longitudinally and washed free of blood with HBSS obtained 
from Gibco (Grand Island, NY). The opened duct was placed 
with the epithelial surface down into a solution of 0.25% 
collagenase IV obtained from Sigma Chemical Co. (St. Louis, 
MO) at room temperature for 10 to 15 min to free up the 
epithelial cells. The duct was then turned over and flushed 
with Williams E (WE) medium (Gibco) containing 10% 
heat-inactivated FBS from Gibco to detach loosely adherent 
BEC. Harvested BEC were pelleted by centrifugation at 1,200 
rpm for 5 min, resuspended in culture medium and examined 
under phase-contrast inverted microscopy. The isolated cells 
were in organoid clusters as previously described (11) and 
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FIG. 1. Immunoperoxidase stain of cultured human BEe showing 
positive stain for cytokeratin (A, original magnification x 560) and 
negative stain for factor VIII-related antigen (B, original magnifi-
cation x 350). 
could not be dispersed into a single cell suspension without 
severely compromising viability and successful expansion in 
culture. Therefore the BEC clusters were suspended in culture 
media and plated after estimating the number of cells present. 
Cell identity was confirmed by their typical structure, with 
positive staining for cytokeratin (AEl/AE3) (Fig. 1A) and 
negative staining for factor V1II-related antigen (Fig. 1B) as 
previously described (11). 
BEC were grown in a serum-free medium consisting of WE 
supplemented with 4 mmollL L-glutamine obtained from 
B & B/Scott (Fiskeville, RD, 24 mmol/L HEPES buffer (Gibco), 
60 ~g/ml gentamycin sulfate (Gibco) and 70 ~g/ml bovine 
pituitary extract (BPE) prepared as described by Hammond, 
Ham and Stampfer (12). In addition, a commercially supplied 
mixture of growth supplements (1 ml each of SGF-7 and 
SGF-9/100 ml of medium obtained from B & B/Scott) was 
included. Recently, the SGF supplements have become un-
available, but we have found that the BEC grow well in KGM 
(Clonetics Corp., San Diego, CAl, which is a medium developed 
for the serum-free culture of human keratinocytes (13). It 
includes many of the same growth factors as the WE media 
described above, including BPE, and results of functional 
assays have been similar using both kinds of medium. 
Cultures for staining were plated on Lab-Tek (Miles Sci-
entific, Naperville, IL) tissue-culture chamber slides, and 
1 x 104 irradiated (22,000 rad) cells of the 3T3 mouse 
fibroblast line obtained from the American Type Culture 
Collection (ATCC) (Rockville, MD) were added to each well as 
feeder cells. Cultures for proliferation assays were plated on 
96-well flat-bottom plates (Costar, Cambridge, MA) previously 
coated with Matrigel (Collaborative Research, Inc., Lexington, 
MA). 
AEC Culture. Human AEC were isolated from intact 
segments of the distal aorta or common iliac arteries obtained 
from organ donors. They were harvested and cultured using 
methods previously described (14). After washing with HESS, 
the open ends of the vessel were clamped, infused with a 0.1% 
collagenase V solution (Sigma Chemical Co.) and incubated for 
30 min at 37° C. Mter flushing with HBSS, the detached AEC 
were pelleted by centrifugation and cultured in endothelial cell 
media consisting of M199 (Gibco) supplemented with 10% 
FBS, 10% pooled human serum, 4 mmol/L L-glutamine, 23 
mmol/L HEPES buffer, 56 ~g/mz amphotericin B (Fungizone, 
Gibco), 10 IU/ml heparin and 100 ~g/ml endothelial cell growth 
factor (Collaborative Research, Lexington, MA). Primary 
cultures were established in 25 cm2 tissue culture flasks 
(Costar) incubated at 37° C in a 5% CO 2 humidified atmo-
sphere. AEC were detached for subculture using a 0.125% 
trypsin/0.05% EDTA solution (Gibco). 
Induction of MHC Antigen Expression. Supernatants were 
harvested from cu ltures of T lymphocytes expanded from 
biopsy samples of liver allografts undergoing rejection (15). 
Approximately 3 x 105 cultured lymphocytes were stimulated 
with 1 x 106 irradiated (4,000 rad) donor splenocytes in each 
well of a 24-well tissue-culture plate (Costar) in lymphocyte 
culture media (LCM). LCM consisted of RPMI-1640 
(B & B/Scott) supplemented with 10% normal human serum, 
4 mmollL L-glutamine, 24 mmol/L HEPES buffer and 60 ~g/ml 
gentamycin sulfate. Supernatants were collected after 48 hr. 
Supernatants from cultures of irradiated splenocytes alone 
were used as controls. 
Supernatants were diluted 1: 1 with WE and BPE growth 
medium and added to BEC grown on tissue-culture chamber 
slides. B3, a monoclona] antibody specific for -y-interferon 
(-y-IFN) (16) (a gift from Centocor, Malvern, PA), was added to 
some wells at the same time as the supernatants. BEC cultures 
were also treated with human recombinant -y-IFN (a gift from 
Genentech, San Francisco, CAl at the concentrations indi-
cated. 
Immunostaining. Expression of MHC antigens was deter-
mined using a standard two-step indirect immunoperoxidase 
technique. BEC cultures were incubated with the activated T 
cell supernatants or with recombinant -y-IFN for 3 days and 
then washed with HBSS. The plastic chambers were removed, 
and the slides were air dried, fixed in acetone for 10 min and 
then stained for MHC antigen expression. Slides were frozen 
if they could not be stained immediately. 
Monoclonal antibodies (MoAbs) reactive with monomorphic 
HLA determinants were used as primary antibodies. MoAb 
PA2.6 recognizes an epitope present on all HLA class I 
molecules (17). MoAb PL8 detects a monomorphic epitope 
found on all HLA-DR molecules. MoAb Tu22 is specific for all 
DQw molecules. MoAb PL15 detects an epitope found on 
HLA-DP molecules. These antibodies were purified immuno-
globulins available through our laboratory's participation in 
the Tenth International Histocompatibility Workshop (18). 
MoAb Leu10, which recognizes a common polymorphic epitope 
present. on HLA-DQ molecules of cells expressing DQwl and 
DQw3 (19), was purchased from Becton Dickinson & Co. 
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(Mountain View, CAl. Peroxidase-conjugated rabbit anti-
mouse antibodies (Dakopatts, Copenhagen, Denmark) were 
used as the secondary reagent. Color development was 
achieved with aminoethyl carbazole, and cells were lightly 
counterstained with Mayer's hematoxylin (Sigma Chemical 
Co.). For negative controls, the primary antibody was omitted. 
Sections of normal livers or livers affected by PBC were 
frozen in OCT compound (Miles Scientific) and used as 
biological controls. The biliary epithelium in normal liver 
tissue did not stain with any of the class II MoAbs tested, 
whereas it stained strongly in the PBC livers with all four 
antibodies. 
Preparation of Alloreactive Lymphocyte Lines. Human 
lymphocytes were isolated from peripheral blood or donor 
spleens by Ficoll-Paque (Pharmacia AB, Uppsula, Sweden) 
gradient separation. Two different types of alloantigen-primed 
lymphocyte lines were used as responder cells in the prolifer-
ation assays. The first consisted of polyspecific primed lym-
phocytes (PPL T), which were prepared by stimulating normal 
lymphocytes with a pool of 10 different irradiated (2,000 rad) 
panel lymphocytes carrying as many HLA antigens as possible. 
Mixed lymphocyte cultures (MLC) were set up in upright 25 
cm2 flasks using equal quantities (1 x 107 cells in 7 ml ofLCM) 
of stimulator and responder cells. After 10 days of culture, the 
lymphocytes were aliquoted and frozen. 
The alloreactive lymphocyte clone DB29 was generated from 
3-day MLC-activated lymphocytes in the two-layer soft agar 
culture method as previously described (20). The resultant 
clone was determined to be specific for HLA-DR2-associated 
DQwl cells. 
Proliferation Assays. The ability of the cultured BEC to 
stimulate in secondary proliferation assays was determined 
using the primed lymphocyte test (PL T). BEC were grown to 
confluence (9 to 14 days) in 96-well flat-bottom tissue culture 
wells coated with Matrigel. Some wells were treated for 3 days 
with 100 IU/ml of"(-IFN. The entire plate was irradiated (2,000 
rad), and each well was washed with RPMI-1640, 3 x 10' 
alloantigen-primed lymphocytes in LCM were added to the 
cultured BEC or to 1 x 105 irradiated (2,000 rad) splenocytes 
isolated from the same donor as the BEC. Background 
proliferation was measured in wells containing BEC with LCM 
alone and in Matrigel-coated wells containing only the primed 
lymphocytes. Final volume in each well was 200 ILl. Plates were 
cultured for 3 days and, during the final 18 to 20 hr of 
incubation, each culture was pulsed with 1 ILCi of 3H_ 
thymidine (specific activity 20 mCi/mmole, New England 
Nuclear Products, Boston, MA). The cultures were harvested 
with a multiple sample harvester (Skatron, Sterling, VA), after 
which wells were treated with trypsin/EDTA to detach any 
remaining adherent cells. The plates were harvested a second 
time, and 3H-thymidine uptake was determined by counting 
filter papers from both harvestings in the same vial using a 
liquid scintillation counter (LKB Instruments, Gaithersburg, 
MD). Results were calculated from the mean cpm in two to 
four replicate wells ± S.D. Test wells with cpm > 4X back-
ground are considered positive. 
AEC were tested for their ability to stimulate primed 
lymphocytes in a similar assay system; 2 x 10' cultured AEC 
were placed in each well of a 96-well flat-bottom tissue-culture 
plate coated with Matrigel. Cells were incubated with or 
without 50 IV/ml "(-IFN, which was the highest concentration 
able to induce MHC class II expression without cytotoxicity 
(data not shown). After 3 days, the weBs were confluent, and 
the PL T was done using the method described above for BEC. 
MoAb Studies. In blocking studies, anti-HLA MoAhs were 
tested for their ability to inhibit the PL T responses. Recog-
FIG. 2. Immunoperoxidase stain of cultured BEC using a mono-
clonal antibody to HLA-DR (PL8). Cultures grown in serum-free 
medium demonstrate only the occasional HLA-DR-positive cell (A, 
original magnification x 350). Cultures treated for 3 days with 
supernatants from stimulated alloreactive T-lymphocyte cultures 
show strong staining for HLA-DR antigens (E, original magnification 
x 350). 
nition of class I HLA antigens was blocked using MoAb W6/32 
(21) (PelFreez, Rogers, AR). Class II recognition was blocked 
using a pool of three MoAbs specific for monomorphic 
determinants found on class II molecules (IVA12 [22]; L243 
and L227 [23]). Hybridomas producing these MoAbs were 
purchased from the ATCC. The antibodies were added to the 
wells at optimal concentrations determined previously. Cell 
numbers and final volume in each well were as described above 
for proliferation assays. 
Statistics. Statistical analysis was performed using the two 
sample t test or the Mann-Whitney test on an IBM computer 
with the "Statistix" software package (NH Analytical 
Software, Roseville, MN). 
RESULTS 
Induction of MHC Antigen Expression on Cultured 
BEC. BEe cultured in serum-free medium showed 
constitutive expression of HLA class I, whereas only 
an occasional cell expressed HLA-DR, HLA-DP or 
HLA-DQ (class II) (Fig. 2A). However, a 3-day treat-
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TABLE 1. Induction of MHC antigen expression on cultured 
human biliary epithelial cells 
Monoclonal HLA 
Degree of cultured BEC staining" 
antibody specificity Untreated y-IFN treated" 
PA2.6 Class 1 +++ + + +C 
PL8 DR + +++ 
Leu10 DQ + 
Tu22 DQ + ++ 
PL15 DP + + 
aStaining of cultured BEC was graded as - (negative); + « 5% 
positive cells); + (20% to 50% positive cells); + + (50% to 80% positive 
cells); + + + (80% to 100% positive cells). 
bCells were cultured in the presence of 100 IV/ml recombinant 
'Y-IFN for 3 days. 
cStaining was more intense than that of untreated cells. 
ment with supernatants from stimulated alloreactive 
T-Iymphocyte cultures induced HLA-DR expression on 
most cells (Fig. 2B). A MoAb to 'Y-IFN inhibited DR 
expression, with staining similar to untreated BEC 
cultures. 
MHC expression was also determined on BEC cul-
tures in WE medium containing 10% FBS. However, 
these cultures showed a higher baseline level of class II 
expression; therefore all subsequent assays were per-
formed on BEC cultured in serum-free medium. 
Treatment of cultured BEC with recombinant 'Y-IFN 
resulted in an increased intensity of staining for 
class I antigens and induced expression of HLA-DR, 
HLA-DP and HLA-DQ (Table 1). However, fewer cells 
stained with HLA-DP- and HLA-DQ-specific anti-
bodies, whereas more than 80% of the cells stained 
strongly for HLA-DR. A concentration of 'Y-IFN as low 
as 10 IV/ml was able to induce some class II antigen 
expression, although 3 days of treatment with at least 
50 IV/ml was needed to induce maximal expression. BEC 
cultures started to show evidence of toxicity (cell death 
and detachment) after more than 3 days of treatment 
with 'Y-IFN or at levels higher than 2,000 IU/ml. 
BEC grown on Matrigel showed the same staining 
characteristics and induction ofMHC as those grown on 
the 3T3 cells. However, Matrigel is derived from mouse 
tissue and thus binds the peroxidase-conjugated anti-
mouse antibody, resulting in intense nonspecific 
staining of the matrix behind the adherent BEC. 
Stimulation of Alloreactive T Lymphocytes by Cul-
tured BEC. Cultured BEC were able to stimulate 
lymphocytes primed against multiple HLA antigens 
(Table 2). However, responses to BEC were much lower 
than responses to splenocytes from the same donor, and 
'Y-IFN treatment of the BEC made little difference in 
their ability to stimulate the primed lymphocytes. 
To confirm that it was the MHC antigens on the BEC 
that were inducing the proliferative responses, mono-
clonal blocking studies were performed (Table 3). The 
class II MoAbs were able to block the response of the 
PPLT line to both untreated BEC and splenocytes by 
more than 50%. A combination of class I and class II 
MoAbs was required to significantly block the 'Y-IFN-
treated BEC. 
A T-cell clone specific for an epitope on the DQwl 
molecule was able to proliferate in response to cultured 
BEC from a donor who was HLA typed as DQwl positive 
(Table 3). These cultured BEC were able to stimulate 
even before 'Y-IFN treatment. The response to untreated 
BEC and splenocytes could be blocked to background 
levels by the class II-specific MoAbs, whereas the class 
I-specific MoAb produced no significant inhibition. The 
anti-class II MoAbs were also able to inhibit the response 
of the clone to 'Y-IFN-treated BEC by more than 70%. 
Comparison of Stimulation by BEC with Stimulation 
by Cultured ABC. The proliferative response of the 
alloreactive T cell lines to cultured BEC was compared 
with their response to cultured AEC tested in the same 
assay system. BEC and AEC from the same donor were 
not available, so the average responses of multiple assays 
with each cell type were compared. Figure 3 demon-
strates that untreated AEC were much stronger stim-
ulators than untreated BEC (24,795 cpm vs. 3,274 cpm; 
p < 0.0001). 'Y-IFN treatment of the cultured stimu-
lators gave similar results (28,553 cpm vs. 3,083 cpm; 
p < 0.0001). However, splenocytes from AEC donors 
stimulated at a level similar to splenocytes from the BEC 
donors (38,238 cpm vs. 43,771 cpm; p = 0.6), indicating 
that the difference in stimulation by the two cell types 
was not due to a difference in the response to the 
different HLA types of the donors. 
DISCUSSION 
Although we and others have published methods for 
the isolation and culture of human biliary epithelium 
(11, 24), this study is the first step in a natural line of 
investigation using BEC in functional assays. We have 
demonstrated that the MHC molecules on the cultured 
BEC carry functional lymphocyte-activating determi-
nants (i.e., they can be recognized by alloprimed T 
lymphocytes in a secondary proliferation assay). The 
blocking of the proliferation by class II-specific MoAbs 
and the response of an alloreactive T-cell clone confirm 
that the stimulation is triggered by recognition ofMHC 
determinants. We have also demonstrated that class I 
MHC antigen expression on cultured human BEC can be 
enhanced, and class II antigen expression can be induced 
in response to alloactivated lymphocyte supernatants. 
The active constituent of these supernatants is most 
likely the 'Y-IFN produced by T cells invading the liver 
allograft. Levels of recombinant 'Y-IFN as low as 10 
IU /ml were able to induce class II expression, although 
maximal expression was reached at concentrations of 50 
to 100 IU/ml. All three class II subregion products 
(HLA-DR, HLA-DP and HLA-DQ) were expressed on 
the 'Y-IFN-treated BEC. 
Although many immunohistochemical studies on 
MHC expression in the transplanted liver exist, the 
significance of the detected alterations has not been 
clear. In normal livers MHC class I antigens are 
expressed on the sinusoidal cells, large vessel and 
sinusoidal endothelia, biliary epithelium, dendritic cells 
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TABLE 2. Response of alloreactive polyspecific primed lymphocytes to cultured biliary epithelial cells as measured in 3-day 
proliferation assays 
Proliferative response (cpm ± S.D.) 
Stimulators 
Responders MatrigelG alone BECb (untreated) BECb (y-IFN treated) Splenocyte&" 
Experiment 1 
Media alone 55 ± 13 451 ± 87 
PPL'fd 1 100 ± 12 2,584 ± 228 
65 ± 14 
28,880 ± 642 
42,835 ± 2,081 PPLT2 79 ± 17 1,821 ± 587 
Experiment 2 
Media alone 49 ± 6 574 ± 111 270 ± 78 
3,042 ± 1,152 
5,707 ± 139 
49 ± 3 
32,403 ± 3,345 
46,413 ± 3,980 
PPLT 1 258 ± 204 4,283 ± 418 
PPLT3 69 ± 20 5,655 ± 1533 
aMatrigel = matrix coated on wells for BEC culture. 
bBEC treated with or without 100 IU/ml recombinant ",/-IFN for 3 days. 
cSplenocytes from the same donor as the BEC. 
dPPLT = polyspecific primed lymphocyte line. 
TABLE 3. Monoclonal blocking studies of BEC-induced stimulation of polyspecific primed lymphocytes and a DQwl-specific 
T-cell clone 
Proliferative response (cpm ± S.D) 
Stimulators 
Responders MoAb" treatment Matrigelb alone BEC" (untreated) BEC" (y-IFN treated) Splenocytell" 
Experiment 1 
Media alone 52 ± 32 493 ± 129 311 ± 129 86 ± 34 
PPLT" None 93 ± 25 3,930 ± 1,305 4,017 ± 1,521 4,366 ± 2,734 
PPLT Class I 93 ± 25 4,326 ± 2,874 3,657 ± 2,755 2,874 ± 228 
PPLT Class II 118 ± 32 1,674 ± 194' 2,358 ± 735 857 ± 183R 
PPLT Class I + II 109 ± 43 1,325 ± 583R 1,358 ± 630S" 998 ± 479B' 
Experiment 2 
Media alone 587 ± 456 180 ± 48 107 ± 71 
Anti-DQwl clone None 51 ± 18 2,326 ± 795 5,005 ± 2,350 47,124 ± 427 
Anti-DQwl clone Class I 1,799 ± 563 5,565 ± 3,246 31,870 ± 3,380 
Anti-DQwl clone Class II 268 ± 59B' 1,596 ± 155" 128 ± 348 
aMonoclonal antibody to either class I or class II antigens or a mixture of both antibodies was added to wells at initiation of proliferation 
assay. 
bMatrigel = matrix coated on wells for BEC culture. 
cBEC treated with or without 100 IU/ml recombinant ",/-IFN for 3 days. 
dSplenocytes from the same donor as the BEC. 
'PPLT = polyspecific primed lymphocyte line. 
flndicates > 50% inhibition; statistical analysis demonstrates marginal significance (p = 0.067) because only duplicate wells were tested. 
81ndicates wells in which monoclonal antibody treatment blocked the response (> 50% inhibition) and that significantly differed from 
untreated wells with p s 0.05 by the Mann-Whitney test. 
and weakly, if at all, on hepatocytes. Class II antigens are 
found only on the sinusoidal cells, capillary endothelium 
and dendritic cells found in the portal connective tissue 
and in the connective tissue immediately subjacent to 
the terminal hepatic venules (5-7, 25). Mter liver 
transplantation, alterations occur in the distribution of 
these antigens. Class I expression is increased on 
hepatocytes and bile ducts, and class II antigens can be 
detected on the biliary epithelium and large vessel 
endothelium (5, 8). How these alterations fit into an 
overall pathogenic scheme in liver allograft rejection has 
yet to be determined, but a hypothesis is expressed 
below. 
The earliest histological evidence of acute cellular 
rejection of both the rat and human liver is focal 
collections of mononuclear cells in the interstitium of 
the portal tracts (1). Sludging of mitotically active 
lymphoid and monocytoid cells in the interstitial portal 
capillaries as early as 2 to 3 days after transplantation 
suggests that some degree of sensitization occurs within 
the graft. It is likely that mononuclear cells are activated 
by antigens on the portal capillaries and dendritic cells. 
The activated lymphocytes would release cytokines such 
as 'Y-IFN that are able to enhance class I and induce class 
II expression on the vascular endothelium and biliary 
epithelium. This induced MHC expression would make 
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FIG. 3. Comparison of the proliferative response of alloreactive T -cell lines (PPL T) to cultured BEC and AEC. Results are the mean of multiple 
assays using five BEC lines, three AEC lines and splenocytes from their respective donors as stimulator cells. n = number of 
stimulator/responder combinations tested. Values shown are net cpm (after subtracting background proliferation) ± S.D. Statistical comparison 
by t test: BEC vs. AEC (untreated), p < 0.000l. BEC vs. AEC ('Y-1FN treated), p < 0.000l. Splenocytes from BEC vs. AEC donors, p = 0.6. 
these structures more susceptible to immune recog-
nition and destruction through direct T cell cytotoxicity 
and indirectly by way of delayed-type hypersensitivity 
responses (3, 26). It is also possible that 'Y-IFN or other 
cytokines released locally may directly i~ure the biliary 
epithelium, as shown by our results. 
Others in the field of organ transplantation have 
presented similar hypotheses concerning MHC antigen 
induction and allograft rejection (27). After studying 
HLA antigen expression in serial liver graft biopsy 
specimens, Gouw et al. (28) have also hypothesized that 
the induction of MHC antigens on bile duct epithelium 
accelerates the alloresponse leading to rejection. 
In vivo, induced expression ofMHC antigens has been 
reported for a number of other inflammatory sites, 
including transplanted kidneys (27), biliary epithelium 
in PBC (4), thyroid epithelium in Graves' disease, 13 cells 
in the diabetic pancreas and salivary ducts in Sjogren's 
syndrome (29). The presence of 'Y-IFN has been demon-
strated at the site of inflammation (30). In vitro, 'Y-IFN 
has been shown to induce de novo class II antigen 
expression on a variety of human cell types, including 
vascular endothelial cells and fibroblasts (31, 32), AEC 
(33), glomerular mesangial cells (34) and thyrocytes 
(35). The class II antigens induced on endothelial cells 
are functional and can be recognized by cytotoxic T cells 
(31). They also are able to act as antigen-presenting 
cells (36). 
We were surprised to find that 'Y-IFN treatment of the 
cultured BEC or AEC does little to increase lymphocyte 
stimulation. Similar work with endothelial cells also 
showed no reproducible difference in the lymphocyte 
response to those cells that expressed class II antigens or 
those that did not at the start of coculture (31). However, 
class II antigens may still have played a role in the T-cell 
stimulation because many of the endothelial cells were 
induced to express class II antigens within 24 hr of 
coculture with lymphocytes, probably because of the 
'Y-IFN released by the T cells. It is likely that a similar 
situation existed in our assays. This is further supported 
by our data showing that untreated BEe, which nor-
mally express very little or no HLA-DQ by immunohis-
tochemistry, were capable of stimulating the HLA-DQ-
specific T-cell clone. 
It is also possible that the very low level of class II 
expression on the untreated BEC was sufficient to 
stimulate the primed lymphocytes. Whereas many cell 
types are considered to be "class II negative," in 
actuality low levels of expression have been demon-
strated in vivo and in vitro. Studies have shown that 
occasional BEC in normal livers do express HLA-DR (7). 
Geppert and Lipsky (32) found a small number of 
DR-positive endothelial cells in their untreated popula-
tions that appeared capable of stimulating allogeneic T4 
cells. 
The proliferative response to cultured BEC, with or 
without 'Y-IFN treatment, or to splenocytes was not 
blocked by the class I MoAb. This is likely due to the 
nature of the responding cell populations. The PPLT 
lines respond most strongly to class II MHC antigens, 
and the T-cell clone tested was specific for an epitope 
found only on class II molecules. Although the response 
of the PPLT line to 'Y-IFN-treated BEC also was not 
significantly blocked by the class II MoAbs, some 
blocking was seen. A combination of both class I and 
class II MoAbs did result in significant blocking. The 
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broad reactivity of the PPLT line, along with the low 
levels of proliferation and the high standard deviations 
inherent with the assay system, likely contributed to 
these discrepancies. 
Studies using endothelial cells have shown that they 
can stimulate a primary lymphocyte response, whereas 
fibroblasts can only stimulate primed alloreactive T-cell 
lines in a secondary proliferation assay (32). Our 
cultured BEC were also not able to activate fresh T 
lymphocytes in a primary response (data not shown). 
However, the responses of the primed T -cell lines were 
relatively low. Because a primary response is usually 
much lower than a secondary response, our negative 
results were not unexpected. 
Despite the fact that we have shown that BEC are 
able to stimulate primed allogeneic lymphocytes and 
therefore probably contribute to their own destruction 
during rejection, they were much less potent stimulators 
than AEC. These results might demonstrate an inherent 
difference in the immunogenicity of the two cell types, 
although it is also possible that the BEC are more 
sensitive to culture conditions that may affect their 
stimulatory capability. 
It is widely recognized that endothelial cells are not 
only potent stimulators of alloresponses but that they 
also can function as accessory cells. A similar hypothesis 
has been forwarded to explain the pathogenesis of the 
vanishing bile duct syndrome, where DR-compatible 
BEC could present incompatible class I MHC or viral 
antigens to the host immune system (37). Although this 
hypothesis is tenable, the less potent stimulatory ca-
pacity of BEC also suggests that other factors may be 
important in making bile ducts susceptible to de-
struction. Although speculative at this point, ischemic 
injury as a result of arterial damage may be of equal or 
greater importance in the ducts' destruction (38). 
Finally, the results of this study demonstrate that 
cultured human BEC are very useful in the study of 
immunological diseases of the human biliary tree. 
Another logical area of investigation is PBC, where it has 
been hypothesized that the aberrant expression of class 
II antigens seen on the bile ducts in PBC livers plays an 
important role in disease pathogenesis (4). Preliminary 
work with lymphocytes isolated from livers affected by 
PBC has shown that they are able to recognize autol-
ogous BEC in vitro. The use of isolated BEC targets in 
conjunction with MoAb blocking studies may permit a 
more precise identification of target antigen(s) in this 
perplexing disease. 
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